Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS… compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in sedation/tranquillisation: Not sedated ‐ at four hours compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in global state: 1. Requiring supplementary medication ‐ antipsychotics compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE may leads to lower global state: 2. Requiring 3 or more injections ‐ over 7 days compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in mental state: 1. No important improvement compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in adverse effects: Movement disorders ‐ dystonia (spasmodic postural… compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Clinically significant response on psychotic symptoms ‐ as defined by each of the studies. · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects, general and specific · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Average change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically significant response on global state · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for rapid tranquillisation ‐ more than 3 injections · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more than 3 injections compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).
1 finding from 1 review